how about a licensing announcement with substantial revenues

How does most every other stock set new highs except Lexaria

Village farms up 20% just on a nasdaq listing
CVSI
ORHOF
ITHUF
CNTTF

I can list 50+ more

interesting 4.99 bid for 900 ask 5 for 1k

Almost passed yesterdays volume already

USD

Fundamental research group put out a $3.50 price target

This is beyond frustrating sector up huge and LXRP not moving. We should be around $2 just based off the sector move. Add in the Altria deal

we all agree prices are low. I wonder why insiders aren't buying. If anyone talks to management that may be a good question.

NOW WHAT. Maybe someone from the company can chime in

Big volume at the close

Ask TRTC shareholders how the reverse split went. This would be a terrible Idea

Analysts go by market cap. Its too low for them to cover it at this point

No I am not implying that at all. All I am trying to point out is that some gaps never get filled. So trying to make this decline attributed to a gap fill I think isn't correct. When a company gets substantial news Sometime you get a gap and it never trades back down to that level because there was a material event that changed the valuation for ever. For example. If a stock is trading at $10 and gets a $20 cash buyout offer and it opens at 19.50 the next day you are likely not going to get a gap fill unless the deal falls through.


I think my previous post was very clear. Psychology and emotion is driving this.

news like this shouldn't matter for gaps. We should be well above the all time high.

Emotion and psychology People are giving up others get frustrated and its a chain reaction

I think $10 is low ball IMO. They need to do a better job getting the word out. Other Marijuana sites I am on don't even speak about this company.

I agree with you that is the lowest value. But if it gets sold then thats all you can value it for the cash.

You can do back of the envelope math and make your own determination.

Say Nicotine gets sold for $500m

Hemp
Pharma
Canpharm


Lets say the other 3 are a combined $500m

$1B /100m shares (round it to a even number account for options and warrants)

There is your $10/ share.


Most companies in this sector that have nothing going for it are valued at $75m. So if you want to go on a Low end valuation the 4 companies X 75m =300m /100m shares $3.

So here is how I see it.


"Look...

Say Lexaria Bioscience were to be currently "worth" a total of $400M - i.e., the sum total of the fair market values of its four subsidiaries:

$100M (Lexaria Pharmaceutical)
+ $100M (Lexaria Canpharm)
+ $100M (Lexaria Hemp)
+ $100M (Lexaria Nicotine)

And say Altria goes ahead and buys Lexaria Nicotine for its fair market value (as per the agreement)... Lexaria Bioscience is not now suddenly worth only $300M (i.e., because Lexaria Nicotine's been sold) - it's still worth $400M:

$100M (Lexaria Pharmaceutical)
+ $100M (Lexaria Canpharm)
+ $100M (Lexaria Hemp)
+ $100M (CASH - received in exchange for Lexaria Nicotine)

We haven't "lost" anything."




Currently there are 77m shares outstanding. so the market cap is currently 112m That is what the market is currently saying they are "worth"



Using your example If they eventually sold off each piece we as LXRP shareholders would receive cash dividend or investors are going to buy up the shares under this amount because of the value. (Think of YAHOO years ago and the stake they had of BABA YHOO JAPAN AND THEIR CASH POSITION) So lets say they sold the nicotine division for $250 million. The stock should be worth a minimum of $3.24 just off that deal based on the 250m / shares outstanding. + you still have the other 3 divisions. I think breaking this up the way Bunka choose to do it was very smart because he can now sell this company multiple times and some companies don't want the marijuana part.

Surprised Insiders aren't buying since after this news we aren't even close to a all time high.

where is everyone. LETS GOOOOOO

low volume in Canada today. 16k shares up 1.58%

Nice boost to take out the 1.57 shares

Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology




KELOWNA, British Columbia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria Bioscience Corp. (LXRP) (CSE:LXX), has entered into a definitive agreement with Altria Group Inc. (MO) to fund the research & development of Lexaria’s patented DehydraTECH™ technology.

Lexaria’s DehydraTECH™ enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability. The partnership will explore innovation in oral, reduced-risk nicotine consumer products and potentially commercialize DehydraTECH™ for oral nicotine delivery.

"This is an incredible milestone for Lexaria Bioscience and our shareholders. We are proud that Altria has chosen to invest in our DehydraTECH™ technology and look forward to reaping the benefits of working with a world-class partner,” states Chris Bunka, CEO of Lexaria Bioscience. “Together we have the opportunity to change nicotine delivery and make a difference in the lives of millions of consumers.”

In exchange for a minority equity interest Altria Ventures Inc., an indirect Altria Group subsidiary, will fund up to US$12 million for Lexaria Nicotine to conduct milestone-based clinical investigations utilizing DehydraTECHTM.

Altria will pay Lexaria Nicotine a royalty on revenue generated from the sale of nicotine products containing DehydraTECH™ and holds the option to acquire 100% ownership in Lexaria Nicotine, at which time royalty payments would stop. Additionally, Altria has the right to initially appoint one of the seven directors on Lexaria Nicotine’s board of directors and, through further phased investments, may have the right to appoint up to three of the seven directors.

About Lexaria Bioscience

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.LexariaBioscience.com

Lexaria Nicotine LLC is a United States domiciled, majority-owned subsidiary of Lexaria Bioscience Corp., focused on reduced-risk nicotine solutions.

www.LexariaNicotineCo.com

For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp and on Facebook https://www.facebook.com/lexariabioscience/

About Altria Group

Altria's wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).

The brand portfolios of Altria's tobacco operating companies include Marlboro®, Black &Mild®, Copenhagen® and Skoal®. Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle®, Columbia Crest®,14 Hands® and Stag's LeapWine Cellars™, and it imports and markets Antinori®, Champagne Nicolas Feuillatte™,Torres® and Villa MariaEstate™ products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission. More information about Altria is available at altria.com and on the Altria Investor app. Take a closer look at Altria and its companies on www.Altria.com

I say we hit $2+ by close tomorrow

Altria group MO released the LXRP news today.

for every trade there is a buyer and a seller. Amazing volume out of the gate.

This stock has so much upside from here its funny the discussion of the day to day moves. Can't wait to see this trading on NASDAQ

yes I agree just showing how ridiculously undervalued this is

If Altria buys out the Nicotine business for lets say $500M thats $6.50 + we still have the other 3 companies of Lexaria.



$500 too aggressive? How about $200m

That would be $2.60 and if you value the other 3 companies at $100M each thats another $3.90 Which brings you to $6.50. These are very conservative numbers.

should be more volume today

More companies are going to do licenses deals with LXRP after this MO news

how long is it going to take to make products from this research deal.

massive volume today. this is a gift to buy at these levels. Just remember they have 3 other divisions to make deals with. This could easily be worth over $20 when all is said and done

300K shares in 22 minutes

BOOM 1.49 +18%

looks like a 8% pop on Canadian side

starts trading at 12PM EST

Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH(tm) Technology for Oral Nicotine

I dont see any other marijuana stocks halted so a deal with another public company both would be halted

Cant wait to see what this news is

The float is 362,192. Management and insiders own 2,091,924 shares.

Its sad PDICAMILLO1 everything you post is spot on but the stock just seems to be dead money.

interesting he did this after the reverse split and running the share price into the ground.